Top Industry Leaders in the Febrile Seizures Market
Latest Febrile Seizures Companies Updates
Eisai Co., Ltd.: Received FDA approval for Fycompa® (perampanel) in October 2023 as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome, potentially offering a new option for children with febrile seizures who experience subsequent epilepsy.
Medtronic plc: Collaborated with the American Academy of Pediatrics in December 2023 to launch the Febrile Seizure Education Initiative, aiming to provide resources and education to parents and healthcare professionals about managing febrile seizures.
UCB Inc.: Partnered with the University of California, San Diego in November 2023 to research the potential of genetic factors in predicting febrile seizure recurrence, paving the way for personalized prevention strategies.
Neuropace, Inc.: Announced the expansion of their RNS® System clinical trial for pediatric epilepsy in August 2023, potentially opening doors for more targeted treatment options for febrile-onset epilepsy.
BrainSentinel, Inc.: Developed the FebriTemp® Smart Thermometer with early seizure detection alerts, currently undergoing FDA review and aiming to provide real-time monitoring for parents and caregivers.
List of Febrile Seizures Key companies in the market:
- Sanofi
- Cardinal Health
- Merck
- Pfizer
- Johnson & Johnson
- Abbott Laboratories
- GlaxoSmithKline plc
- Cephalon Inc.
- Shire
